Pharmaceutical company (Taiho Oncology in the U.S.)
Appears in 1 story
Leads REZILIENT3 and global zipalertinib development with Cullinan
Patients with EGFR exon 20 insertion lung cancer have had almost no targeted options in the front-line setting. A phase 3 trial presented Sept. 13 in Seoul changed that. Adding the oral drug zipalertinib to chemotherapy delayed tumor progression by six months compared with chemotherapy alone.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
